DelSite Biotechnologies, Inc. Announces Development of Unique Synthetic Typhoid Vi Polysaccharide Vaccine Candidate

IRVING, Texas, June 26, 2008 (PRIME NEWSWIRE) -- DelSite Biotechnologies, Inc., a wholly-owned subsidiary of Carrington Laboratories, Inc. (OTCBB:CARN), today announced that it has developed a proprietary synthetic typhoid fever vaccine candidate based on a novel plant polysaccharide (high-molecular-weight polygalacturonic acid, HPGA) that holds the potential to greatly enhance production and use of typhoid fever vaccine worldwide.